Directorio

We are doing this study to find out if an experimental drug called CVN424 (the study drug) can help people diagnosed with advanced Parkinson's Disease (PD) who are on a stable dose of medication and continue to experience three of more hours of "OFF-time." OFF-time is a term that refers to the time when people experience PD symptoms between doses of medicine. We want to know if the study drug can reduce symptoms and lower that amount of time.

We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

We are doing this study to find out if an investigational drug called tinlarebant (the study drug) is safe and useful for treating geographic atrophy (GA).

We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.

We are doing this study to find out if the combination of two hormonal drugs, giredestrant and fulvestrant, are a safe and effective option if they are given with the study doctor's choice of a class of medicines called CDK4/6 inhibitors to people who have ER-positive, HER2-negative breast cancer that is resistant to standard treatments.

We are doing this study to find out what factors affect how well platelet rich plasma (PRP) injections work for people who choose to get them to treat a problem with their hip, knee, or shoulder joint. We hope the information we get from this study will help us find out what effects, if any, factors like age, gender, medical conditions, or injury history have on the outcomes of these injections.

We are doing this study to find out if the combination of an experimental drug called ONC201 (the study drug) with paxalisib is an effective option for patients with a diffuse midline glioma (DMG). We also want to see how much of these drugs are absorbed by tumor tissue in patients with brain tumors.